RPG Active Pharma to Acquire Raghava Life Sciences' API Business for Rs 135 Crore
RPG Life Sciences' wholly owned subsidiary, RPG Active Pharma, is acquiring the active pharmaceutical ingredients (API) and intermediates business of Raghava Life Sciences for up to Rs 135 crore. The acquisition, subject to regulatory approvals and customary closing conditions, will be executed through a slump sale on a going-concern basis. It includes 22 commercialized APIs and seven development-stage assets across multiple therapeutic areas. This marks RPG Active Pharma's second strategic acquisition, aiming to expand its manufacturing footprint, product portfolio, and market presence in the growing API sector.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 41/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 3 Sept, 04:55 am. Other outlets followed.